Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

Brentuximab vedotin

EU orphan designation number: EU/3/11/939   
Active ingredient: Brentuximab vedotin
Indication: Treatment of cutaneous T-cell lymphoma
Sponsor: Takeda Pharma A/S
Dybendal Alle 10, 2630 Taastrup, Danmark

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/01/2012 Orphan designation EMA/OD/100/11 (2012)125 of 11/01/2012
23/10/2013 Transfer of orphan designation EMA/OD/100/11/T/01 (2013)7105 of 21/10/2013
26/03/2015 Change of name and/or address of sponsor